Short explainers for founders and the consultants who guide them. Each one cites the FDA guidance it summarises, and says plainly whether a regulatory professional has reviewed it yet.
Choosing an FDA pathway 510(k), De Novo, PMA or exempt: how class, predicates and risk decide the route. (draft)